Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. ("Agios" or "the Company") (NASDAQ:AGIO). Investors who purchased Agios securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGIO.

Agios Investigation Details

On July 21, 2026, Agios issued a press release "announcing topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase (PK) activator, in patients aged 16 years or older with sickle cell disease." The press release disclosed that "[t]he trial did not demonstrate the level of differentiation required to support continued development" and "therefore, Agios has decided not to advance tebapivat in sickle cell disease." Following this news, Agios's stock price dropped $2.70 per share, or 6.74%, to close at $37.36 per share on July 21, 2026.

What's Next for Agios Investors?

If you are aware of any facts relating to this investigation or purchased Agios securities, you can assist this investigation by visiting the firm's site: bgandg.com/AGIO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Agios Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Agios Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC